Clincosm LogoSign in Get a demo

Experience in Borderline Ovarian Tumors

Sponsor
University of Palermo (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05791838
Collaborator
(none)
86
Enrollment

Study Details

Study Description

Brief Summary

Borderline ovarian tumors (BOTs) comprise 15-20% of primary ovarian neoplasms and represent an independent disease entity among epithelial ovarian cancers. The present study aimed to report the 8-year experience of a single center on the management and outcomes of consecutive BOTs patients. From January 2010 to December 2017, all patients with BOTs undergoing surgical treatment were included. Demographic, clinical, and pathological data were reviewed retrospectively.

Condition or Disease Intervention/Treatment Phase

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    86 participants
    Observational Model:
    Cohort
    Time Perspective:
    Retrospective
    Official Title:
    Borderline Ovarian Tumors: Results of a Retrospective, Single-center Experience
    Anticipated Study Start Date :
    Mar 1, 2023
    Anticipated Primary Completion Date :
    Mar 1, 2023
    Anticipated Study Completion Date :
    Mar 1, 2023

    Outcome Measures

    Primary Outcome Measures

    1. Oncological outcome [through study completion, an average of 1 year]

      Patients who underwent surgery for BOT

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    • Age > 18 years,

    • Patients affected by borderline ovarian tumors (BOT) of any histological type and any FIGO stage,

    • Women undergoing surgical treatment with both laparoscopic and laparotomic approaches.

    Exclusion Criteria:
    • Women affected by ovarian cancers

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • University of Palermo

    Investigators

    • Principal Investigator: Basilio Pecorino, M.D., University of Catania
    • Study Director: Paolo Scollo, M.D. Ph.D., University of Catania
    • Study Chair: Antonio Simone Laganà, M.D. Ph.D., University of Palermo
    • Study Chair: Andrea Etrusco, M.D., University of Palermo

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Andrea Etrusco, Principal investigator, University of Palermo
    ClinicalTrials.gov Identifier:
    NCT05791838
    Other Study ID Numbers:
    • BOT-1
    First Posted:
    Mar 30, 2023
    Last Update Posted:
    Mar 30, 2023
    Last Verified:
    Mar 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Andrea Etrusco, Principal investigator, University of Palermo
    Conservative surgery
    Micropapillary patterns
    Surgical staging
    Additional relevant MeSH terms:
    Ovarian Neoplasms

    Study Results

    No Results Posted as of Mar 30, 2023